Tea Polyphenol (-)-Epigallocatechin-3-Gallate Inhibits DNA Methyltransferase and Reactivates Methylation-Silenced Genes in Cancer Cell Lines

Cancer Research

Volumn 63, Issue 22, 2003, Pages 7563-7570

  Fang, Ming Zhu ^a   Wang, Yimin ^a   Ai, Ni ^b   Hou, Zhe ^a   Sun, Yi ^a   Lu, Hong ^a   Welsh, William ^b   Yang, Chung S ^a  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYSTEINE; DNA METHYLTRANSFERASE; EPIGALLOCATECHIN GALLATE; GLUTAMINE; METHYLGUANINE METHYLTRANSFERSE; MUTL HOMOLOGUE 1 PROTEIN; POLYPHENOL; PROLINE; PROTEIN; PROTEIN P16; RETINOIC ACID RECEPTOR BETA; SERINE; TRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CATALYSIS; COLON CANCER; CONTROLLED STUDY; DNA METHYLATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE; ESOPHAGUS CANCER; GENE ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; HYDROGEN BOND; MISMATCH REPAIR; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; TEA; WESTERN BLOTTING;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CATECHIN; CELL DIVISION; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENZYME INHIBITORS; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P16; HUMANS; MODELS, MOLECULAR; NEOPLASM PROTEINS; NUCLEAR PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RECEPTORS, RETINOIC ACID;

EID: 0345275879     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Yang, C. S., Maliakal, P., and Meng, X. Inhibition of carcinogenesis by tea. Annu. Rev. Pharmacol. Toxicol., 42: 25-54, 2002.
2. Meng, X., Sang, S., Zhu, N., Lu, H., Sheng, S., Lee, M. J., Ho, C. T., and Yang, C. S. Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats. Chem. Res. Toxicol., 15: 1042-1050, 2002.
3. Lu, H., Meng, X., Li, C., Sang, S., Patten, C., Sheng, S., Hong, J., Bai, N., Winnik, B., Ho, C. T., and Yang, C. S. Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. Drug Metab. Dispos., 31: 452-461, 2003.
4. Cheng, X. Structure and function of DNA methyltransferases. Annu. Rev. Biophys. Biomol. Struct., 24: 293-318, 1995.
5. Esteller, M. CpG island hypermethylation and tumor suppresor genes: a booming present, a brighter future. Oncogene, 21: 5427-5440, 2002.
6. Jones, P. A., and Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3: 415-428, 2002.
7. Jones, P. A., and Takai, D. The role of DNA methylation in mammalian epigenetics. Science (Wash. DC), 293: 1068-1070, 2001.
8. Lichtenstein, A. V., and Kisseljova, N. P. DNA methylation and carcinogenesis. Biochemistry (Mosc.), 66: 235-255, 2001.
9. Nguyen, C. T., Gonzales, F. A., and Jones, P. A. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res., 29: 4598-4606, 2001.
10. Rice, J. C., Massey-Brown, K. S., and Futscher, B. W. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene, 17: 1807-1812, 1998.
11. Robertson, K. D., Ait-Si-Ali, S., Yokochi, T., Wade, P. A., Jones, P. L., and Wolffe, A. P. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet., 25: 338-342, 2000.
12. Rountree, M. R., Bachman, K. E., and Baylin, S. B. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet., 25: 269-277, 2000.
13. Clark, S. J., and Melki, J. DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene. 21: 5380-5387, 2002.
14. Christman, J. K. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene, 21: 5483-5495, 2002.
15. Zhou, L., Cheng, X., Connolly, B. A., Dickman, M. J., Hurd, P. J., and Homby, D. P. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J. Mol. Biol., 321: 591-599, 2002.
16. Cheng, J. C., Matsen, C. B., Gonzales, F. A., Ye, W., Greer, S., Marquez, V. E., Jones, P. A., and Selker, E. U. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst., 95: 399-409, 2003.
17. Bender, C. M., Pao, M. M., and Jones, P. A. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res., 58: 95-101, 1998.
18. Wang, Y., Fang, N. Z., Liao, J., Yang, G-Y., Nie, Y., Song, Y., So, C., Xu, X., Wang, L-D., and Yang C. S. Hypermethylation associated inactivation of retinoic acid receptor β (RARβ) in human esophageal squamous cell carcinoma. Clin. Cancer Res., in press, 2003.
19. Belinsky, S. A., Nikula, K. J., Baylin, S. B., and Issa, J. P. Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc. Natl. Acad. Sci. USA, 93: 4045-4050, 1996.
20. Adams, R. L., Rinaldi, A., and Seivwright, C. Microassay for DNA methyltransferase. J Biochem Biophys Methods, 22: 19-22, 1991.
21. Jones, G., Willett, P., Glen, R. C., Leach, A. R., and Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 267: 727-748. 1997.
22. Herman, J. G., Graft, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
23. Palmisano, W. A., Divine, K. K., Saccomanno, G., Gilliland, F. D., Baylin, S. B., Herman, J. G., and Belinsky, S. A. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res., 60: 5954-5958, 2000.
24. Kresty, L. A., Mallery, S. R., Knobloch, T. J., Song, H., Lloyd, M., Casto, B. C., and Weghorst, C. M. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res., 62: 5295-5300, 2002.
25. Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., and Herman, J. G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res., 59: 793-797, 1999.
26. Bovenzi, V., and Momparler, R. L. Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells. Cancer Chemother. Pharmacol., 48: 71-76, 2001.
27. Murata, H., Khattar, N. H., Kang, Y., Gu, L., and Li, G. M. Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene, 21: 5696-5703, 2002.
28. Ng, M. H., Chung, Y. F., Lo, K. W., Wickham, N. W., Lee, J. C., and Huang, D. P. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood, 89: 2500-2506, 1997.
29. 6-methylguanine. Mutagenesis, 17: 483-487, 2002.
30. O'Gara, M., Klimasauskas, S., Roberts, R. J., and Cheng, X. Enzymatic C5-cytosine methylation of DNA: mechanistic implications of new crystal structures for HhaL methyltransferase-DNA-AdoHcy complexes. J. Mol. Biol., 261: 634-645, 1996.
31. Detich, N., Theberge, J., and Szyf, M. Promoter-specific activation and demethylation by MBD2/demethylase. J. Biol. Chem., 277: 35791-35794, 2002.
32. Aparicio, A., Eads, C. A., Leong, L. A., Laird, P. W., Newman, E. M., Synold, T. W., Baker, S. D., Zhao, M., and Weber, J. S. Phase 1 trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother. Pharmacol., 51: 231-239, 2003.
33. Shi, H., Wei, S. H., Leu, Y. W., Rahmatpanah, F., Liu, J. C., Yan, P. S., Nephew, K. P., and Huang, T. H. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res., 63: 2164-2171, 2003.
34. Saunders, N., Dicker, A., Popa, C., Jones, S., and Dahler, A. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res., 59: 399-404, 1999.
35. Shaker, S., Bernstein, M., Momparler, L. F., and Momparler, R. L. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk. Res., 27: 437-444, 2003.
36. Yoshida, M., Furumai, R., Nishiyama, M., Komatsu, Y., Nishino, N., and Horinouchi, S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol., 48(Suppl. 1): S20-S26, 2001.
37. Turker, M. S. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene, 21: 5388-5393, 2002.
38. Laird, P. W., Jackson-Grusby, L., Fazeli, A., Dickinson, S. L., Jung, W. E., Li, E., Weinberg, R. A., and Jaenisch, R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell, 81: 197-205, 1995.
39. Eads, C. A., Nickel, A. E., and Laird, P. W. Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min+) Dnmt1-hypomorphic mice. Cancer Res., 62: 1296-1299, 2002.
40. Eden, A., Gaudet, F., Waghmare, A., and Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science (Wash. DC), 300: 455, 2003.
41. Gaudet, F., Hodgson, J. G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J. W., Leonhardt, H., and Jaenisch, R. Induction of tumors in mice by genomic hypomethylation. Science (Wash. DC), 300: 489-492, 2003.
42. Tsubaki, J., Choi, W. K., Ingermann, A. R., Twigg, S. M., Kim, H. S., Rosenfeld, R. G., and Oh, Y. Effects of sodium butyrate on expression of members of the IGF-binding protein superfamily in human mammary epithelial cells. J. Endocrinol., 169: 97-110, 2001.